Mirum Appoints Global Blood’s Radovich as Its Chief Operating Officer

Mirum Pharmaceuticals (NASDAQ: [[ticker:MIRM]]) has added Peter Radovich to its C-suite as its chief operating officer. Radovich was most recently executive vice president, operations for South San Francisco-based Global Blood Therapeutics (NASDAQ: [[ticker:GBT]]).

Foster City, CA-based Mirum, which launched in 2018 after licensing its lead compound from Shire, is developing liver disease drugs. The biotech says it plans to start a rolling FDA submission of its lead drug next quarter: The compound, maralixibat, is under evaluation for cholestatic pruritus, or severe itching, associated with a rare genetic disorder called Alagille syndrome.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.